Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS -- Ignore unavailable to you. Want to Upgrade?

To: Lighthouse who wrote (319)	7/30/1998 4:57:00 PM
From: Vector1	Respond to of 410

<<Personally I would drop every indication except an arthrscopic Carticel procedure. Long term I believe you will need a two step arthroscopic procedure to drive widespread adoption.>> I agree. One of the criticisms of the tracking stock structure is that it provides an incentive for companies to be less than vigilent in accessing R&D cost since they use after tax dollars and don't take the earnings hit. If GENZL and GENZ were not separate stocks GENZ would take about a 40c per year hit on earnings. My guess is they would have already sold off their Diacrin interest and partnered on Carticel reducing the loss in about half. V1